Sector News

Takeda’s dengue vaccine candidate delivers continued protection

June 11, 2022
Life sciences

Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases. Furthermore, there were no important safety risks identified among the overall population throughout the four and a half years following vaccination during the phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.

TIDES is a double-blind, randomised, placebo-controlled trial is evaluating the safety and efficacy of two TAK-003 doses. It involves the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.

The new long-term results back-up previously published TIDES data which demonstrated the candidate vaccine met its primary endpoint of overall 80.2% efficacy at the 12-month follow-up, as well as all secondary endpoints for which there were a sufficient number of dengue cases at 18-months follow-up, including 90.4% hospitalised dengue.

“The burden of dengue is far reaching, and over half of the world’s population is at risk of dengue each year,” said Eng Eong Ooi from the Duke-NUS Medical School. “There is an urgent need for impactful prevention tools to combat the disease. The long-term TIDES results indicate that TAK-003 could be an important addition to the limited tools we have to prevent dengue, particularly given the demonstrated protection against hospitalisations.”

“Dengue is a complex, global disease, and the TIDES trial was designed to account for this, including both dengue-naïve and dengue-exposed populations in Latin America and Asia where outbreaks are prevalent, with evaluation over four and a half years,” added Gary Dubin, president, global vaccine business unit at Takeda. “We are proud that the results continue to demonstrate the efficacy and safety of TAK-003 and its ability to provide long-term protection against dengue.”

While the long-term follow-up for the primary two-dose series has been completed, the TIDES trial continues to evaluate the safety and efficacy of a booster dose. TIDES trial is Takeda’s largest interventional clinical trial to date – enrolling more than 20,000 healthy children and adolescents of four to 16 years of age, across eight dengue-endemic countries.

by John Pinching

Source: pharmatimes.com

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.